Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bausch + Lomb Corporation ( (BLCO) ) has shared an update.
Bausch + Lomb Corporation announced the acquisition of Whitecap Biosciences, enhancing its clinical pipeline with therapies targeting glaucoma and geographic atrophy (GA). This strategic move aims to address unmet medical needs and improve existing treatments, potentially offering significant advancements for patients with these ophthalmic conditions.
More about Bausch + Lomb Corporation
Bausch + Lomb is a global leader in eye health, offering a wide range of products including contact lenses, lens care, ophthalmic pharmaceuticals, and surgical devices. Founded in 1853, the company operates in nearly 100 countries with a robust research and development, manufacturing, and commercial presence.
YTD Price Performance: -1.33%
Average Trading Volume: 549,191
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.25B
For detailed information about BLCO stock, go to TipRanks’ Stock Analysis page.